|
Childhood asthma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to determine if NAT1 polymorphisms confer increased risk for developing asthma in children exposed to SHS.<b>Methods:</b> White participants in the Cincinnati Childhood Allergy and Air Pollution Study (<i>n</i> = 359) were genotyped for 10 <i>NAT1</i> variants.
|
31809667 |
2019 |
|
Xeroderma Pigmentosum
|
0.010 |
Biomarker
|
disease |
BEFREE |
Genetic polymorphism (glutathione S-transferase M1; T1; P1 (GSTM1; GSTT1; GSTP1); N-acetyltransferase 1; 2 (NAT1; NAT2); cytochrome P450 1B1 (CYP1B1); sulfotransferase 1A1 (SULT1A1); myeloperoxidase (MPO); catechol-O-methyltransferase (COMT); manganese superoxide dismutase (MnSOD); NAD(P)H:quinone oxidoreductase (NQO1); X-ray repair cross-complementing group 1; 3 (XRCC1; XRCC3) and xeroderma pigmentosum complementation group (XPD)) was assessed in peripheral blood lymphocytes.
|
30042310 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.010 |
Biomarker
|
disease |
BEFREE |
To investigate whether smoking in patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon beta (IFN-β) is associated with the relapse rate and whether there is an interaction between smoking and human leukocyte antigen (HLA)-DRB1*15:01, HLA-A*02:01, and the N-acetyltransferase-1 (<i>NAT1</i>) variant rs7388368A.
|
29343473 |
2018 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Human arylamine N-acetyltransferase 1 (NAT1) has been associated with cancer cell growth and invasion, but the underlying molecular mechanisms remain unknown.
|
29518119 |
2018 |
|
Hereditary Nonpolyposis Colorectal Cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Moreover, significant interactions were observed between NAT1 acetylation and CYP1B1 rs1056827 and meat consumption.Our results suggest that xenobiotic-metabolizing SNPs are not only associated with CRC risk in patients with Lynch syndrome in Taiwan but also interact with meat consumption to modify the disease risk..
|
28714190 |
2018 |
|
Lynch Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Moreover, significant interactions were observed between NAT1 acetylation and CYP1B1 rs1056827 and meat consumption.Our results suggest that xenobiotic-metabolizing SNPs are not only associated with CRC risk in patients with Lynch syndrome in Taiwan but also interact with meat consumption to modify the disease risk..
|
28714190 |
2018 |
|
Endothelial dysfunction
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In ISO-CHF rats, oral administration of Nat (1, 3, 9 mg·kg<sup>-1</sup>·d<sup>-1</sup>) or Ipt (3 mg·kg<sup>-1</sup>·d<sup>-1</sup>) for 60 days significantly improved cardiac dysfunction, reversed cardiac remodeling, significantly attenuated the pathological increases in BNP levels, and improved endothelial dysfunction by adjusting the balance between endothelin and NO systems.
|
27890915 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We tested functional haplotype-based NAT1 and NAT2 gene polymorphisms in relation to risk of lymphoma overall and its major B cell subtypes, diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukaemia (CLL).
|
25689677 |
2016 |
|
Mitochondrial Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Mutations in SLC25A4 encoding the mitochondrial ADP/ATP carrier AAC1 are well-recognized causes of mitochondrial disease.
|
27693233 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
NAT1 and NAT2 genetic polymorphisms and environmental exposure as risk factors for oesophageal squamous cell carcinoma: a case-control study.
|
25886288 |
2015 |
|
Malignant neoplasm of esophagus
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that NAT1 and NAT2 genetic polymorphisms may influence the risk of oesophageal cancer upon exposure to environmental carcinogens.
|
25886288 |
2015 |
|
Candidiasis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In multivariate analysis, concomitant use of fluconazole for candidiasis was the only factor associated with reduced risk for hepatotoxicity (adjusted odds ratio, 0.372; 95% confidence interval, 0.145-0.957), while serostatus of hepatitis B or C virus, NAT1 and NAT2 acetylator types, or receipt of combination antiretroviral therapy was not.
|
25184238 |
2014 |
|
Multiple Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
NAT1 emerged as a genetic effect modifier of tobacco smoke exposure in MS susceptibility.
|
24625537 |
2014 |
|
Node-positive breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
NAT1 is a possible prognostic biomarker for lymph node-positive breast cancer.
|
25528056 |
2014 |
|
Leukoplakia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
NAT1 rapid acetylation could not modulate the risk of leukoplakia and cancer (OR=0.9, 95% CI: 0.6-1.3; OR=1.0, 95% CI: 0.7-1.4, respectively).
|
23168701 |
2012 |
|
Leukoplakia, Oral
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We undertook this study to check whether polymorphisms at NAT1 can modulate the risk of oral leukoplakia and cancer either alone or in combination with NAT2.
|
23168701 |
2012 |
|
Progressive supranuclear palsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigated whether specific single nucleotide polymorphisms (SNPs) in genes encoding enzymes of xenobiotic detoxification, mitochondrial functioning, or oxidative stress response, including debrisoquine 4-hydroxylase, paraoxonase 1 and 2, N-acetyltransferase 1 and 2 (NAT2), superoxide dismutase 1 and 2, and PTEN-induced putative kinase are associated with PSP.
|
22424094 |
2012 |
|
Carcinoma of Male Breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we identified NAT1 as a possible prognostic biomarker for MBC, as suggested by NAT1 positivity corresponding to better outcome.
|
22333393 |
2012 |
|
Malignant neoplasm of male breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we identified NAT1 as a possible prognostic biomarker for MBC, as suggested by NAT1 positivity corresponding to better outcome.
|
22333393 |
2012 |
|
Adenocarcinoma of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we have knocked down NAT1 in the colon adenocarcinoma cell-line HT-29 and found a marked change in cell morphology that was accompanied by an increase in cell-cell contact growth inhibition and a loss of cell viability at confluence.
|
21347396 |
2011 |
|
Hepatitis B
|
0.010 |
Biomarker
|
disease |
BEFREE |
The overall yield of HBV DNA-positive, HBsAg-negative units was 1 in 21,282 (18 cases), higher when using ID-NAT than MP8-NAT (1:9862 vs. 1:51,011; p < 0.01).
|
19682332 |
2010 |
|
T-Cell Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We found a two-fold increased risk of T-cell lymphoma among those possessing the NAT1*10 genotype compared to those with other NAT1 genotypes; including an OR of 2.0 (95% CI: 1.0-2.4) for those heterozygous or homozygous for NAT1*10 genotypes.
|
19809881 |
2010 |
|
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Specifically, polymorphisms in GSTT1 were associated with follicular lymphoma survival; and polymorphisms in CYP2E1, GSTP1, and NAT1 were associated with survival of chronic lymphocytic leukemia/small lymphocytic lymphoma.
|
20029944 |
2010 |
|
Dermatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that slow metabolic phenotype of NAT2 maybe one of risk factor for TCE-induced hypersensitivity dermatitis and combined slow acetylator phenotypes of NAT1 and NAT2 further increase such risk.
|
19834256 |
2009 |
|
Allergic sensitization
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Para-phenylenediamine and allergic sensitization: risk modification by N-acetyltransferase 1 and 2 genotypes.
|
19663877 |
2009 |